Recent

% | $
Quotes you view appear here for quick access.

Alnylam Pharmaceuticals, Inc. Message Board

robert.vince 55 posts  |  Last Activity: Mar 25, 2015 8:54 AM Member since: Aug 30, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • robert.vince robert.vince Feb 23, 2015 10:36 PM Flag

    Hey Floored! Good to hear from you. Hope all is well with you too. With a little luck (wife not putting kebosh on it), I'll retire at the end of May. Done with driving 100 miles a day, time to start working on hobbies like music, gardening and the neverending battle to clean up my basement. Hope I've found you in good health and spirits.

  • robert.vince robert.vince Feb 23, 2015 10:34 PM Flag

    Not the same article, but the same news:
    http://www.bizjournals.com/boston/blog/bioflash/2015/02/celldex-shares-spike-after-fda-news-regarding.html

  • robert.vince robert.vince Feb 23, 2015 10:34 PM Flag

    Hi Cygnus7, real article, but you know yahoo, they won't let you post links. I'll try after I post this.

  • robert.vince robert.vince Feb 23, 2015 11:04 AM Flag

    good question.... maybe late wakers from the west coast?

  • robert.vince robert.vince Feb 23, 2015 10:00 AM Flag

    don't typos suck? Would love if yahoo would let authors edit their posts after posting

  • Celldex's Rindopepimut (Rintega(R)) Receives FDA Breakthrough Therapy Designation for the Treatment of Adult Patients with EGFRvIII-positive Glioblastoma
    "The FDA's decision to grant Breakthrough Designation underscores rindopepimut's therapeutic potential for patients with glioblastoma," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics. "These patients have extremely limited treatment options, with only three new drugs approved in more than twenty years. Emerging clinical data suggests that rindopepimut may offer an improvement over existing standard of care for EGFRvIII-positive patients. With continued positive data, we look forward to working closely with the FDA to support potential approval of rindopepimut as expeditiously as possible."

  • Reply to

    Are these beads safe.

    by pearsby09 Feb 20, 2015 10:57 AM
    robert.vince robert.vince Feb 21, 2015 12:02 AM Flag

    Then the patient would probably die, but since the beads are safely inside the canister, with no way of escaping, your scenario is far fetched.

  • robert.vince robert.vince Feb 5, 2015 9:09 AM Flag

    Based on its novel therapeutic mechanism and supporting clinical data, Time Magazine recently named our Hemopurifier® to the following lists: “The 25 Best Inventions of 2014” and “11 Remarkable Health Advances from 2014“.
    In regards to our FDA approved clinical program, I am pleased to share that we have enrolled our first patient who has initiated a feasibility study protocol that is being conducted at the DaVita Medical Center in Houston, Texas. Under this feasibility study protocol, we will enroll ten end-stage renal disease (ESRD) patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety of Hemopurifier® therapy in an infectious disease model. Upon successful completion the study, we will seek FDA clearance to conduct pivotal efficacy studies required for market clearance to treat chronic viral indications. However, our current feasibility study also contributes safety data, which is the sole human challenge to advance Hemopurifier® therapy against category “A” threats whose virulence does not allow for human efficacy studies to be conducted. While this may be our first human clinical study in the United States, Hemopurifier® therapy has been previously administered with success overseas in Ebola, HIV and HCV-infected individuals. In closing, I hope you follow the clinical progression of our Hemopurifier® as a broad-spectrum countermeasure against virulent viral pathogens.

  • A convergence of global warming, environmental encroachment and the expansion of international transportation has contributed to an increased incidence of viral epidemics. In most cases, the viruses underlying these epidemics are not treatable with proven antiviral drug or vaccine countermeasures. In the absence of such therapeutic options, supportive care has remained the sole option to combat virulent pathogens, including category “A” viruses, which the National Institute of Allergy and Infectious Diseases (NIAID) categorize as posing the greatest risk to national security and public health. The viruses of greatest concern to NIAID include; Ebola, Marburg, Dengue, Smallpox, Junin, Machupo, Guanarito, Lassa, Hanta, Rift Valley, Crimean Congo, and Charpare and Lujo virus, which were new additions to the category “A” pathogen list in 2014. Beyond these threats are viruses genetically modified to be agents of bioterrorism, emerging drug resistant strains of HIV and Hepatitis C virus, and activated latent viruses that contribute to sepsis mortality and organ transplant rejection. To address the breadth of viral pathogens that threaten mankind, therapeutic innovation that reaches beyond traditional drug mechanisms will need to emerge.

    Yesterday, we launched an FDA approved clinical study based on our vision for treating infectious viral pathogens. Instead of deploying a drug mechanism to inhibit the replication of a specific virus, we created the Aethlon Hemopurifier®, a medical device designed to capture viral pathogens through affinity attachment to a unique structure that enveloped viruses co-opt from host cells during replication. Based on extensive clinical research and collaborations, we believe our Hemopurifier® is the first broad-spectrum therapeutic candidate with demonstrated ability to capture different strains, species, and families of viruses.

  • robert.vince robert.vince Feb 3, 2015 8:42 AM Flag

    Green PolkaDot Box America's premier online membership club for organic and non-GMO natural foods at wholesale pricing. GPDB is the only major online store that refuses to carry products or ingredients containing GMO. GPDB leverages proprietary technology with its dynamic, interactive website and member relationship management software to provide a unique shopping and membership experience. GPDB plans to grow membership with families looking for natural non-GMO products and organic choices for up to a 60% discount off retail prices.

  • Green PolkaDot Box reported today that sales this past January were sharply higher, approximately $370,000 for the month, a 109% increase from December 2014. The Company also reports record gains in gross margin, average revenue per order and customer growth. These increases resulted from rising inventory levels, Appethyl(R) sales and GPDB's Health Merchant program.

    Increased January sales helped GPDB achieve positive monthly cash flow and earnings for the first time in its 3-year operating history. Gross margin on sales were a record high at more than 50%, yielding EBITDA of approximately $87,212 or 23.5%. Average revenue per general goods order increased from approximately $71 to $93 or 31%!

    "Achieving full inventory, with the help of our investment partners, has a lot to do with our success this month. January results are a harbinger of what is expected for the full year," says GPDB CEO, Rod Smith. "We anticipate Appethyl(R) will become a household name. It has proven to reduce appetite and cravings for sweets and produce significant weight loss".

    GPDB also added 1,548 new customers in January, an increase of 39% over December's total. (These figures do not include the 1,795 orders which GPDB received from Amazon during January.)

    Mr. Smith also commented on the new Health Merchant Program; how GPDB has developed additional customer growth and the higher sales. "A single Health Merchant may have the ability to refer hundreds, if not thousands, of new customers due to their direct influence over health-minded consumers within their reach. In January, one Health Merchant referred over 700 new customers to GPDB".

    GPDB has registered 108 Health Merchants at an enrollment fee of $1,995, plus a monthly fee of $100. Health Merchant stores are scheduled for activation with a national launch in late February. Watch our video on the Health Merchant Program.

    Sentiment: Strong Buy

  • You don't have to go searching for Cytosorb, go to Aferetica's homepage and there it is as big as day.
    Of course yahoo won't let me post the link.

  • CytoSorbents Corporation a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation in critically-ill and cardiac surgery patients, announced the receipt of $385,642, net of transaction costs, in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority (NJEDA). Funds will be used to help expand manufacturing of CytoSorb® and support sales of CytoSorb® internationally.
    The New Jersey Technology Business Tax Certificate Transfer Program enables approved Technology and Biotechnology Businesses with Net Operating Losses to sell their Unused Net Operating Loss Carryover (NOL) and Unused Research and Development Tax Credits (R&D Tax Credits) for at least 80% of the value of the tax benefits to a profitable corporate taxpayer in the State of New Jersey that is not an Affiliated Business. This allows Technology and Biotechnology Businesses with Net Operating Losses to turn their tax losses and credits into cash to buy equipment or facilities, or for other Allowable Expenditures. The New Jersey Economic Development Authority (NJEDA) determines eligibility, and the New Jersey Division of Taxation determines the value of the tax benefits (NOL and R&D Tax Credits).

    Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, "As a high growth, international therapeutics company with distribution of CytoSorb® in 28 countries around the world, and continued expansion of our manufacturing, R&D and administrative facility in New Jersey, we thank the continued support of the NJEDA. Over the past 6 years, we have obtained nearly $7.5 million in non-dilutive government grants, contracts and other funding, an important part of our overall financing strategy."

    Sentiment: Strong Buy

  • robert.vince robert.vince Jan 22, 2015 12:29 PM Flag

    Only cause nobody knows about it yet. You're in on the bottom floor and they either go bankrupt or we get rich. If you go to their site, they have a customer count listed at the top of the page, after months of losing customers, they're finally firing on all cylinders, adding new users every day. They got a million dollar line of credit to keep items in stock, which is why they were losing customers. I bought at $3 a share, then bought lots more when it hit a buck, but I don't think there are many shares to go around right now, hence the low trading volume. They're trying to uplist this year, thats when it takes off imho. Good luck to you (and me)!

  • Green PolkaDot Box Incorporated (GPDB) reports today that sales in all categories through the middle of January are sharply higher than the comparable 2014 period coming in at $210,000. The blended gross margin on sales exceeds 50%. Combined sales, as of January 15th, are more than 19% above total December sales, suggesting GPDB will likely earn profit on operations for the first time in its history.

    "Of course, I'm pleased with the results," says GPDB CEO, Rod Smith. "But we are just getting started. Customer growth is also trending higher. Through mid-January 2015, we added over 950 new customers, meeting our projections. A significant portion of new customer growth is coming through GPDB's Health Merchant program."
    Through Amazon, January sales of Appethyl(R) have exceeded management's expectations and are expected to continue strong. After two weeks of sales on Amazon, Appethyl(R) by Green PolkaDot Box already ranks high in the "Shakes and Powders" sub-category. GPDB is also close to establishing additional channels of sales and distribution.

    Preparations to GPDB's Up Listing

    On a separate business front, the Company is conducting an audit. CEO Rod Smith states: "We are preparing to position GPDB to become fully-reporting and list on a major exchange. We believe 2015 will be our break out year."

    Green PolkaDot Box America's premier online membership club for organic and non-GMO natural foods at wholesale pricing. GPDB is the only major online store that refuses to carry products or ingredients containing GMO. GPDB leverages proprietary technology with its dynamic, interactive website and member relationship management software to provide a unique shopping and membership experience. GPDB plans to grow membership with families looking for natural non-GMO products and organic choices for up to a 60% discount off retail prices.

    Sentiment: Strong Buy

  • robert.vince robert.vince Jan 20, 2015 10:36 AM Flag

    Early Financial Impact Seems Positive

    The initial impact of these initiatives appear to be positive, we believe; earlier this month, the company announced that sales advanced about 65% sequentially in December 2014. This reflected a roughly 31% advance in its core online general goods business, as higher inventory levels enabled order fulfillment, augmented by the early positive response to the Health Merchant program.

    The company also noted that Appethyl sales through Amazon in early January were ahead of expectations. Through January 5, aggregate revenue from Appethyl and the Health Merchant program were north of $65,000, which represents about 37% of total monthly sales in December 2014, according to management, which believes that January monthly revenue could be on-track to beat that of November and December combined.

  • robert.vince robert.vince Jan 16, 2015 11:56 AM Flag

    Early Financial Impact Seems Positive

    The initial impact of these initiatives appear to be positive, we believe; earlier this month, the company announced that sales advanced about 65% sequentially in December 2014. This reflected a roughly 31% advance in its core online general goods business, as higher inventory levels enabled order fulfillment, augmented by the early positive response to the Health Merchant program.

    The company also noted that Appethyl sales through Amazon in early January were ahead of expectations. Through January 5, aggregate revenue from Appethyl and the Health Merchant program were north of $65,000, which represents about 37% of total monthly sales in December 2014, according to management, which believes that January monthly revenue could be on-track to beat that of November and December combined.

    Sentiment: Strong Buy

  • From Zacks
    Several recent initiatives by Green PolkaDot Box (GPDB), a membership club that offers organic and natural products to its members at attractive prices, have shown early momentum, we believe. These include the company’s recently introduced Health Merchant program, marketing for appetite suppressant Appethyl and the positive impact of a new credit line. We believe the market opportunity for GPDB is significant, as consumer interest in organic products is growing rapidly. In our view, the company continues to add new ways to tap into this high growth market.

    Health Merchant Program

    In November 2014, the company unveiled a new Health Merchant program that enables health professionals and others to launch a turnkey, self-branded online health products store, with Green PolkaDot Box providing back office and logistics. The company’s target market for this program includes doctors with disease prevention practices, nutritionists, chiropractors, gym operators, personal fitness trainers and pharmacists, among others.

    For $300 up to $1,995, depending on which package the health practitioner selects, Health Merchants get an online health and wellness store that offers a broad range of natural products at competitive prices. For a $100 monthly service fee, GPDB handles the logistics, from product acquisition, inventory storage, website hosting and maintenance, liability insurance, online order processing to shipping and customer service.

    Health Merchants also get access to a media kit including informational videos that GPDB will update frequently. Green PolkaDot Box also offers weekly specials, supported with electronic marketing. The company believes these promotions give GPDB a higher than average conversion rate of first time website visitors into repeat customers.

    Sentiment: Strong Buy

  • Arch Therapeutics, Inc. (OTCQB: ARTH) , developer of the AC5 Surgical Hemostatic Device™, obtained positive results when AC5™ was subjected to a standardized medical device test for irritation potential. The irritation test in animals is a major component of the International Organization for Standardization's (ISO) required panel of biocompatibility testing necessary for medical devices prior to use in humans. AC5 is a unique development-stage hemostasis product being evaluated to control bleeding and fluid loss in order to provide faster and safer surgical and interventional care.

    In this standard three-day in vivo rabbit model study, AC5 tested in relevant amounts was well tolerated, gave a zero (0) irritation score and was classified as a negligible irritant using a standardized scoring system. A device in this study can be classified and scored as negligible (0.0-0.4), slight (0.5-1.9), moderate (2.0-4.9) or severe (5.0-8.0). Results from this biocompatibility safety study indicate that AC5's peptide structure and mechanism of action, which is based on the formation of a local physical-mechanical barrier at the wound site, does not promote application site erythema or edema, which are indices of irritation. This study represents further data supporting the absence of toxicity for AC5, and represents an important step in demonstrating biocompatibility of AC5.

    Arch Therapeutics President and CEO Terrence Norchi, MD, stated, "These promising results underscore our positive expectations for AC5. We look forward to additional studies with AC5 that indicate its potential value in terms of safety, efficacy and user-friendliness."

  • Stellar Biotechnologies, Inc announced today that the Company's management team will present at the 7th Annual Biotech Showcase 2015 conference, being held at the Parc 55 Wyndham Hotel in San Francisco, CA, on Tuesday, January 13 at 2:30 p.m. PST.

    Stellar Biotechnologies' Presentation Details
    Date: Tuesday, January 13, 2015
    Time: 2:30 p.m. PST
    Location: Parc 55 Wyndham Hotel, 55 Cyril Magnin Street, San Francisco, CA
    Room & Track: C-Mission II (4th Floor)

    About Biotech Showcase 2015
    The Biotech Showcase 2015 conference takes place January 12-14, 2015, at the Parc 55 Wyndham Hotel located in Union Square, San Francisco, California. Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry's largest annual healthcare investor conferences. Now in its seventh year, Biotech Showcase is expected to attract upwards of 1,500 attendees.

ALNY
104.06+4.42(+4.44%)Mar 27 4:00 PMEDT